Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,668 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Terminated No phase listed Observational Accepts healthy volunteers

The Role of Estrogen in Adipocyte Remodeling Following Surgical Menopause

NCT03631680
View directory record Official record
Conditions
Menopause Surgical, Estrogen Deficiency, Adiposity
Interventions
Bilateral Oophorectomy Surgery
Procedure
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 21, 2026, 1:18 AM EDT
Suspended Not applicable Interventional

A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination

NCT06168942
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
Interventions
Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet
Device
Lead sponsor
Jaguar LAA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea

NCT07577661
View directory record Official record
Conditions
Obstructive Sleep Apnea, Sleep-disordered Breathing
Interventions
Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition
Other · Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 21, 2026, 1:18 AM EDT
Recruiting Phase 3 Interventional

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib, Active Comparator, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Not applicable Interventional Results available

Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.

NCT01477320
View directory record Official record
Conditions
Gastrointestinal Hemorrhage, Clostridium Difficile Colitis
Interventions
Pantoprazole 40 mg IV daily and tube feed., Placebo and tube feed
Drug · Other
Lead sponsor
Mohamed Saad
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 21, 2026, 1:18 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Cannabidiol in Sanfilippo Syndrome

NCT06333041
View directory record Official record
Conditions
Sanfilippo Syndrome, Mucopolysaccharidosis III
Interventions
Epidiolex, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
4 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation

NCT02554903
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Macitentan 10mg, Placebo sugar pill
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
50
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 21, 2026, 1:18 AM EDT
Terminated Not applicable Interventional

Home Exercise Adherence in Physical Therapy

NCT02822755
View directory record Official record
Conditions
Adherence
Interventions
Home Exercise Program and Adherence Logs
Other
Lead sponsor
Evan J. Petersen
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 2Phase 3 Interventional

Confirmation of Diet as a Treatment for Gulf War Illness

NCT05675878
View directory record Official record
Conditions
Gulf War Syndrome, Gulf War Illness
Interventions
Dietary Intervention
Behavioral
Lead sponsor
American University
Other
Eligibility
50 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Fort Lauderdale, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

NCT00221403
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone oral solution, Valproate Oral Solution, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 7 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia

NCT02059135
View directory record Official record
Conditions
Preeclampsia
Interventions
Recombinant human antithrombin (ATryn), Normal Saline 0.9%
Biological · Other
Lead sponsor
rEVO Biologics
Industry
Eligibility
16 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 2 Interventional

Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa

NCT01642550
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 21, 2026, 1:18 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

NCT05609968
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Sacituzumab Govitecan, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
16
States / cities
Mobile, Alabama • Oceanside, California • Clermont, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 2 Interventional

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

NCT02673476
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALS-008176, Placebo
Drug
Lead sponsor
Alios Biopharma Inc.
Industry
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Eustis, Florida • Hialeah, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 2 Interventional

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

NCT06862791
View directory record Official record
Conditions
Obesity or Overweight
Interventions
AZD9550, AZD6234, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
29
States / cities
Dothan, Alabama • Vestavia Hills, Alabama • Cerritos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Not listed Phase 1Phase 2 Interventional

Tolerability and Efficacy of RJX in Patients With COVID-19

NCT04708340
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions
Rejuveinix (RJX) Active Comparator, Placebo Comparator
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Houston, Texas • New Braunfels, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing

NCT01892891
View directory record Official record
Conditions
Healthy
Interventions
VBY-036
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 21, 2026, 1:18 AM EDT
Not yet recruiting Phase 2 Interventional

Tolerability and Efficacy of CBD Extract for RLS Treatment

NCT07224932
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
BRC-002, Placecbo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 79 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Not applicable Interventional Results available

Nicotine Withdrawal Symptoms and Smoking Relapse

NCT01511614
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Transcranial Direct Current Stimulation, sham, Nicotine patch, Placebo patch, Varenicline Pill, Placebo pill, Motivational Interviewing
Device · Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 21, 2026, 1:18 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

NCT07273838
View directory record Official record
Conditions
Heart Failure, Acute Kidney Injury
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparative Efficacy of Floss and Essential Oil/CPC+Zn Mouthwashes in Reducing Dental Plaque and Gingivitis

NCT07029438
View directory record Official record
Conditions
Dental Plaque, Gingivitis
Interventions
Mouthwash, Floss, Toothbrush, Toothpaste
Drug · Device
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 21, 2026, 1:18 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

HomeStyles-Adults of Chinese Heritage

NCT06136793
View directory record Official record
Conditions
Healthy Lifestyle, Home Environment Related Disease, Cardiometabolic Disease, Systemic Inflammatory Response, Health Behavior, Dietary Habits, Physical Inactivity, Self Efficacy, Gut Microbiota, Diabetes Mellitus
Interventions
HomeStyles-China
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
30 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 21, 2026, 1:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study to Assess Wound Healing Efficacies of Different Adhesive Bandages

NCT04040933
View directory record Official record
Conditions
Wound Healing
Interventions
Marketed Adhesive Bandage #1, Marketed Bandage #2, Non-Marketed Bandage #1, Non-Marketed Bandage #2, Non-Marketed Adhesive Bandage #3, Non-Marketed Adhesive Bandage #4, Non-Marketed Adhesive Bandage #5
Device
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
25 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 21, 2026, 1:18 AM EDT